-
Je něco špatně v tomto záznamu ?
En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature
K. Mori, D. D'Andrea, DV. Enikeev, S. Egawa, SF. Shariat,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
- MeSH
- cystektomie * MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- nádory močového měchýře patologie chirurgie MeSH
- progrese nemoci MeSH
- urologické chirurgické výkony MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
PURPOSE OF REVIEW: Conventional transurethral resection of bladder tumor (cTURBT) is the standard approach to the diagnosis and treatment of nonmuscle invasive bladder cancer. However, it suffers from inherent limitations such as insufficient assessment of resection depth and the need for intravesical tumor fragmentation that hampers histopathological evaluation. We summarize recent clinical data on en bloc resection of bladder tumor (ERBT), a method that promises to overcome these limitations. RECENT FINDINGS: The PubMed/Medline databases were searched for reports on ERBT focusing on trends in the last 2 years. ERBT provides greater resection quality, making up to 95% of detrusor muscle available for pathological evaluation. ERBT also allows detection of the muscularis mucosae thus facilitating T1 substaging. Available data demonstrate no significant difference in perioperative morbidity. No conclusions can be drawn on the impact of either modality on tumor recurrence and progression, as the available data is too underpowered. SUMMARY: ERBT is gaining acceptances as there is increasing evidence that it improves the quality of resected specimens. There seems to be no difference in perioperative morbidity between ERBT and cTURBT. The impact of ERBT on important endpoints such as recurrence and progression remains to be fully elucidated in further studies.
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology The Jikei University School of Medicine Tokyo Japan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025300
- 003
- CZ-PrNML
- 005
- 20201222155141.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000000697 $2 doi
- 035 __
- $a (PubMed)31724997
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria. Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- 245 10
- $a En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature / $c K. Mori, D. D'Andrea, DV. Enikeev, S. Egawa, SF. Shariat,
- 520 9_
- $a PURPOSE OF REVIEW: Conventional transurethral resection of bladder tumor (cTURBT) is the standard approach to the diagnosis and treatment of nonmuscle invasive bladder cancer. However, it suffers from inherent limitations such as insufficient assessment of resection depth and the need for intravesical tumor fragmentation that hampers histopathological evaluation. We summarize recent clinical data on en bloc resection of bladder tumor (ERBT), a method that promises to overcome these limitations. RECENT FINDINGS: The PubMed/Medline databases were searched for reports on ERBT focusing on trends in the last 2 years. ERBT provides greater resection quality, making up to 95% of detrusor muscle available for pathological evaluation. ERBT also allows detection of the muscularis mucosae thus facilitating T1 substaging. Available data demonstrate no significant difference in perioperative morbidity. No conclusions can be drawn on the impact of either modality on tumor recurrence and progression, as the available data is too underpowered. SUMMARY: ERBT is gaining acceptances as there is increasing evidence that it improves the quality of resected specimens. There seems to be no difference in perioperative morbidity between ERBT and cTURBT. The impact of ERBT on important endpoints such as recurrence and progression remains to be fully elucidated in further studies.
- 650 12
- $a cystektomie $7 D015653
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a nádory močového měchýře $x patologie $x chirurgie $7 D001749
- 650 _2
- $a urologické chirurgické výkony $7 D013520
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a D'Andrea, David $u Department of Urology, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Enikeev, Dmitry V $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
- 700 1_
- $a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Department of Urology, Weill Cornell Medical College, New York, New York. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 1 (2020), s. 41-47
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31724997 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155137 $b ABA008
- 999 __
- $a ok $b bmc $g 1599445 $s 1115986
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 30 $c 1 $d 41-47 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20201125